Breast cancer in Serbia: preparations for a screening program

Author(s):  
A Jovicevic Bekic ◽  
R Dzodic ◽  
Z Milosevic
2008 ◽  
Vol 149 (32) ◽  
pp. 1491-1498 ◽  
Author(s):  
Imre Boncz ◽  
Andor Sebestyén ◽  
Lajos Döbrőssy ◽  
Zoltán Péntek ◽  
Attila Kovács ◽  
...  

Célkitűzés: Az országos kiterjedésű, szervezett emlőszűrési program 2002 januárjában indult el Magyarországon a 45–65 év közötti nők számára 2 éves szűrési intervallummal. A dolgozat célja a szervezett emlőszűrési program részvételi mutatóinak meghatározása, beleértve a szűrési és diagnosztikus célú képalkotó emlőfelvételek gyakoriságának elemzését. Adatok és módszerek: Az elemzésben szereplő adatok az Országos Egészségbiztosítási Pénztár finanszírozási adatbázisából származnak, és a 2000–2005 közötti 6 évet ölelik fel. A 45–65 éves nők körében meghatározták azok arányát, akik a szervezett szűrést megelőző két évben (2000–2001), illetve a program első két ciklusában (2002–2003, 2004–2005) akár szűrési, akár diagnosztikai célú képalkotó emlővizsgálaton vettek részt. Eredmények: A szűrési célú képalkotó emlőfelvételen részt vettek aránya (átszűrtség) a 2000–2001-es 7,4%-ról a 2002–2003-as, illetve 2004–2005-ös szervezett emlőszűrési ciklusban 34,0, illetve 29,5%-ra emelkedett. A diagnosztikus célú képalkotó emlőfelvételen részt vettek aránya (átvizsgáltság) pedig ugyanezen időszakokban 19,8%-ról 22,1 (2002–2003), illetve 23,2%-ra (2004–2005) emelkedett. Az országos lefedettség (átszűrtség + átvizsgáltság) ennek megfelelően a szervezett szűrés hatására 26,2%-ról (2000–2001) 53,5%-ra (2002–2003), illetve 50,8%-ra (2004–2005) nőtt a vizsgált kétéves ciklusban a 45–65 év közötti nők esetében. Következtetés: A magyar emlőszűrési program kezdeti részvételi arányai 2004–2005-ben kissé csökkentek; az emlőrák miatti halálozás érdemi csökkentéséhez ennek emelése szükséges.


2019 ◽  
Vol 65 (5) ◽  
pp. 664-671
Author(s):  
Ilya Pyatnitskiy ◽  
O. Puchkova ◽  
Viktor Gombolevskiy ◽  
Lyudmila Nizovtsova ◽  
Natalya Vetsheva ◽  
...  

The article presents a literature review of the PubMed database and the Cochrane library, aimed at analyzing the current situation and problems in the field of breast cancer screening in the world and Russia to form an idea of the key elements in organizing an effective screening program in the Russian healthcare system, as well as the possibilities of using new technologies when organizing such programs.


2018 ◽  
Vol 10 (7) ◽  
Author(s):  
Inaki Lete ◽  
Mirian Aguiar ◽  
Arguine Andonegui ◽  
Nagore Zeberio ◽  
Maria Cuadra ◽  
...  

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Lorena Squillace ◽  
Lorenzo Pizzi ◽  
Flavia Rallo ◽  
Carmen Bazzani ◽  
Gianni Saguatti ◽  
...  

AbstractWe conducted a cross-sectional study to assess the likelihood of returning for routine breast cancer screening among women who have experienced a false-positive result (FPR) and to describe the possible individual and organizational factors that could influence subsequent attendance to the screening program. Several information were collected on demographic and clinical characteristics data. Electronic data from 2014 to 2016 related to breast screening program of the Local Health Authority (LHA) of Bologna (Italy) of women between 45 and 74 years old were reviewed. A total of 4847 women experienced an FPR during mammographic screening and were recalled to subsequent round; 80.2% adhered to the screening. Mean age was 54.2 ± 8.4 years old. Women resulted to be less likely to adhere to screening if they were not-Italian (p = 0.001), if they lived in the Bologna district (p < 0.001), if they had to wait more than 5 days from II level test to end of diagnostic procedures (p = 0.001), if the diagnostic tests were performed in a hospital with the less volume of activity and higher recall rate (RR) (p < 0.001) and if they had no previous participation to screening tests (p < 0.001). Our results are consistent with previous studies, and encourages the implementation and innovation of the organizational characteristics for breast cancer screening. The success of screening programs requires an efficient indicators monitoring strategy to develop and evaluate continuous improvement processes.


Cancers ◽  
2021 ◽  
Vol 13 (5) ◽  
pp. 1177
Author(s):  
In Young Choi ◽  
Sohyun Chun ◽  
Dong Wook Shin ◽  
Kyungdo Han ◽  
Keun Hye Jeon ◽  
...  

Objective: To our knowledge, no studies have yet looked at how the risk of developing breast cancer (BC) varies with changes in metabolic syndrome (MetS) status. This study aimed to investigate the association between changes in MetS and subsequent BC occurrence. Research Design and Methods: We enrolled 930,055 postmenopausal women aged 40–74 years who participated in a biennial National Health Screening Program in 2009–2010 and 2011–2012. Participants were categorized into four groups according to change in MetS status during the two-year interval screening: sustained non-MetS, transition to MetS, transition to non-MetS, and sustained MetS. We calculated multivariable-adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) for BC incidence using the Cox proportional hazards models. Results: At baseline, MetS was associated with a significantly increased risk of BC (aHR 1.11, 95% CI 1.06–1.17) and so were all of its components. The risk of BC increased as the number of the components increased (aHR 1.46, 95% CI 1.26–1.61 for women with all five components). Compared to the sustained non-MetS group, the aHR (95% CI) for BC was 1.11 (1.04–1.19) in the transition to MetS group, 1.05 (0.96–1.14) in the transition to non-MetS group, and 1.18 (1.12–1.25) in the sustained MetS group. Conclusions: Significantly increased BC risk was observed in the sustained MetS and transition to MetS groups. These findings are clinically meaningful in that efforts to recover from MetS may lead to reduced risk of BC.


2020 ◽  
Author(s):  
Markus Kuksis ◽  
Yizhuo Gao ◽  
William Tran ◽  
Christianne Hoey ◽  
Alex Kiss ◽  
...  

Abstract Background Patients with metastatic breast cancer (MBC) are living longer, but development of brain metastases often limits their survival. We conducted a systematic review and meta-analysis to determine the incidence of brain metastases in this patient population. Methods Articles published from January 2000 to January 2020 were compiled from four databases using search terms related to: breast cancer, brain metastasis, and incidence. The overall and per patient-year incidence of brain metastases were extracted from studies including patients with HER2+, triple negative, and hormone receptor (HR)+/HER2- MBC; pooled overall estimates for incidence were calculated using random effects models. Results 937 articles were compiled, and 25 were included in the meta-analysis. Incidence of brain metastases in patients with HER2+ MBC, triple negative MBC, and HR+/HER2- MBC was reported in 17, 6, and 4 studies, respectively. The pooled cumulative incidence of brain metastases was 31% for the HER2+ subgroup (median follow-up: 30.7 months, IQR: 24.0 – 34.0), 32% for the triple negative subgroup (median follow-up: 32.8 months, IQR: 18.5 – 40.6), and 15% among patients with HR+/HER2- MBC (median follow-up: 33.0 months, IQR: 31.9 – 36.2). The corresponding incidences per patient-year were 0.13 (95% CI: 0.10 – 0.16) for the HER2+ subgroup, 0.13 (95%CI: 0.09 – 0.20) for the triple negative subgroup, and only 0.05 (95%CI: 0.03 – 0.08) for patients with HR+/HER2- MBC. Conclusion There is high incidence of brain metastases among patients with HER2+ and triple negative MBC. The utility of a brain metastases screening program warrants investigation in these populations.


Sign in / Sign up

Export Citation Format

Share Document